Teva Pharmaceutical Industries Limited (TEVA)
After hours:
| Previous Close | 8.53 |
| Open | 8.65 |
| Bid | 8.73 x 3100 |
| Ask | 8.89 x 21500 |
| Day's Range | 8.61 - 8.98 |
| 52 Week Range | 6.78 - 11.45 |
| Volume | |
| Avg. Volume | 9,018,762 |
| Market Cap | 9.774B |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.63 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | Nov 27, 2017 |
| 1y Target Est | 10.20 |
- Business Wire
Teva Announces Early Tender Results of its Debt Tender Offer, Increases to Tender Caps and Election of Early Settlement
TEL AVIV, Israel, March 13, 2023--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) ("Teva") announced today the early tender results in connection with its previously announced tender offers (the "Offers") and that it is increasing the tender caps as specified below for the following series of notes issued by finance subsidiaries of Teva and guaranteed by Teva:
- Business Wire
Teva and Natco Announce Launch of additional strengths for the Generic Version of Revlimid® (lenalidomide capsules), in the U.S.
PARSIPPANY, N.J. & TEL AVIV, Israel & HYDERABAD, India, March 09, 2023--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and NATCO Pharma Limited (NSE: NATCOPHARM; BSE: 524816), announced today the launch of additional strengths for the generic version of Revlimid®1 (lenalidomide capsules), in 2.5 mg, and 20 mg strengths, in the United States.
- Business Wire
Teva to Present at the Barclays Global Healthcare Conference
TEL AVIV, Israel & PARSIPPANY, N.J., March 07, 2023--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Eli Kalif, EVP and Chief Financial Officer will present at the Barclays Global Healthcare Conference on Tuesday, March 14, 2023. The presentation will begin at 10:15 A.M. Eastern Time.
